XML 56 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating activities:      
Net income (loss) $ 707 $ (512) $ 52
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:      
Depreciation and amortization 127 178 182
Deferred income taxes (6) (94) 22
Share-based compensation 27 46 26
Non-cash restructuring charges 17 60 0
Amortization of convertible senior notes and lease financing obligations 22 32 31
Loss on sales of subsidiaries, net of gain 15 0 0
Loss on debt extinguishment 22 14 0
Impairment losses 0 470 0
Other, net 4 21 16
Changes in operating assets and liabilities:      
Receivables (530) 103 (348)
Prepaid expenses and other current assets 6 (56) (69)
Medical claims and benefits payable (226) 263 226
Amounts due government agencies (574) 341 473
Accounts payable and accrued liabilities 45 (12) (4)
Deferred revenue (21) (34) 92
Income taxes 51 (16) (26)
Net cash (used in) provided by operating activities (314) 804 673
Investing activities:      
Purchases of investments (1,444) (2,697) (1,929)
Proceeds from sales and maturities of investments 2,445 1,759 1,966
Purchases of property, equipment and capitalized software (30) (86) (176)
Net cash received from sale of subsidiaries 190 0 0
Net cash paid in business combinations 0 0 (48)
Other, net (18) (38) (19)
Net cash provided by (used in) investing activities (1,143) 1,062 206
Financing activities:      
Repayment of credit facility (300) 0 0
Cash paid for partial settlement of 1.125% Conversion Option (623) 0 0
Cash received for partial settlement of 1.125% Call Option 623 0 0
Cash paid for partial termination of 1.125% Warrants (549) 0 0
Proceeds from senior notes offerings, net of issuance costs 0 325 0
Proceeds from borrowings under credit facility 0 300 0
Other, net 18 11 19
Net cash (used in) provided by financing activities (1,193) 636 19
Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents (364) 378 486
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period 3,290 2,912 2,426
Cash, cash equivalents, and restricted cash and cash equivalents at end of period 3,290 2,912 2,426
Supplemental cash flow information:      
Income taxes 240 7 153
Interest 93 78 66
Schedule of non-cash investing and financing activities:      
Common stock issued in exchange for 1.625% Convertible Notes 131 193 0
Component of 1.625% Convertible Notes allocated to additional paid-in capital, net of income taxes (23) (32) 0
Net increase to additional paid-in capital 108 161 0
Common stock used for stock-based compensation (6) (22) (8)
Details of sales of subsidiaries:      
Decrease in carrying amount of assets (327) 0 0
Decrease in carrying amount of liabilities 85 0 0
Transaction costs (15) 0 0
Cash received from buyers 242 0 0
Loss on sales of subsidiaries, net of gain (15) 0 0
Details of business combinations:      
Fair value of assets acquired 0 0 (186)
Fair value of liabilities assumed 0 0 28
Payable to seller 0 0 8
Amounts advanced for acquisitions 0 0 102
Net cash paid in business combinations 0 0 (48)
Details of change in fair value of derivatives, net:      
Change in fair value of derivatives, net 0 0 0
1.125% Call Option      
Details of change in fair value of derivatives, net:      
Change in fair value of derivatives, net 577 255 (107)
1.125% Conversion Option      
Details of change in fair value of derivatives, net:      
Change in fair value of derivatives, net (577) (255) 107
1.125% Notes      
Financing activities:      
Repayment of principal amount of Notes (298) 0 0
1.625% Notes      
Financing activities:      
Repayment of principal amount of Notes $ (64) $ 0 $ 0